MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jhep.2022.08.025

Медицинская библиотека · Journal of hepatology · 2022

Non-invasive tests for clinically significant portal hypertension after HCV cure.

Semmler Georg, Lens Sabela, Meyer Elias L, Baiges Anna, Alvardo-Tapias Edilmar, Llop Elba, Tellez Luis, Schwabl Philipp, Mauro Ezequiel, Escudé Laia, Díez Cristina, Ibañez-Samaniego Luis, Puente Ángela, Fortea José Ignacio, Abadía Marta, Zanetto Alberto, Conthe Andrés, Hernandez-Évole Helena, Luzko Scheid Irina Sofia, Jia Jidong, Yoshiji Hitoshi, Francque Sven M, Tsochatzis Emmanuel A, Russo Francesco Paolo, Crespo Gonzalo, Forns Xavier, Bañares Rafael, Villanueva Càndid, Hernández-Gea Virginia, Reiberger Thomas, Bosch Jaume, García Pagán Juan Carlos, Mandorfer Mattias, A study by the Baveno Cooperation: an EASL consortium

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND & AIMS: Non-invasive tests (NITs) for clinically significant portal hypertension (CSPH; hepatic venous pressure gradient [HVPG] ≥10 mmHg) have predominantly been studied in patients with active HCV infection. Investigations after HCV cure are limited and have yielded conflicting results. We conducted a pooled analysis to determine the diagnostic/prognostic utility of liver stiffness measurement (LSM)/platelet count (PLT) in this setting.

METHODS

A total of 418 patients with pre-treatment HVPG ≥6 mmHg who achieved sustained virological response (SVR) and underwent post-treatment HVPG measurement were assessed, of whom 324 (HVPG/NIT-cohort) also had paired data on pre-/post-treatment LSM/PLT. The derived LSM/PLT criteria were then validated against the direct endpoint decompensation in 755 patients with compensated advanced chronic liver disease (cACLD) with SVR (cACLD-validation-cohort).

RESULTS

HVPG/NIT-cohort: Among patients with cACLD, the pre-/post-treatment prevalence of CSPH was 80%/54%. The correlation between LSM/HVPG increased from pre- to post-treatment (r = 0.45 vs. 0.60), while that of PLT/HVPG remained unchanged. For given LSM/PLT values, HVPG tended to be lower post- vs. pre-treatment, indicating the need for dedicated algorithms. Combining post-treatment LSM/PLT yielded a high diagnostic accuracy for post-treatment CSPH in cACLD (AUC 0.884; 95% CI 0.843-0.926). Post-treatment LSM <12 kPa & PLT >150 G/L excluded CSPH (sensitivity: 99.2%), while LSM ≥25 kPa was highly specific for CSPH (93.6%). cACLD-validation-cohort: the 3-year decompensation risk was 0% in the 42.5% of patients who met the LSM <12 kPa & PLT >150 G/L criteria. In patients with post-treatment LSM ≥25 kPa (prevalence: 16.8%), the 3-year decompensation risk was 9.6%, while it was 1.3% in those meeting none of the above criteria (prevalence: 40.7%).

CONCLUSIONS

NITs can estimate the probability of CSPH after HCV cure and predict clinical outcomes. Patients with cACLD but LSM <12 kPa & PLT>150 G/L may be discharged from portal hypertension surveillance if no co-factors are present, while patients with LSM ≥25 kPa require surveillance/treatment.

LAY SUMMARY: Measurement of liver stiffness by a specific ultrasound device and platelet count (a simple blood test) are broadly used for the non-invasive diagnosis of increased blood pressure in the veins leading to the liver, which drives the development of complications in patients with advanced liver disease. The results of our pooled analysis refute previous concerns that these tests are less accurate after the cure of hepatitis C virus (HCV) infection. We have developed diagnostic criteria that facilitate personalized management after HCV cure and allow for a de-escalation of care in a high proportion of patients, thereby decreasing disease burden.

Для цитирования: Semmler Georg, Lens Sabela, Meyer Elias L, Baiges Anna, Alvardo-Tapias Edilmar, Llop Elba, Tellez Luis, Schwabl Philipp, Mauro Ezequiel, Escudé Laia, Díez Cristina, Ibañez-Samaniego Luis, Puente Ángela, Fortea José Ignacio, Abadía Marta, Zanetto Alberto, Conthe Andrés, Hernandez-Évole Helena, Luzko Scheid Irina Sofia, Jia Jidong, Yoshiji Hitoshi, Francque Sven M, Tsochatzis Emmanuel A, Russo Francesco Paolo, Crespo Gonzalo, Forns Xavier, Bañares Rafael, Villanueva Càndid, Hernández-Gea Virginia, Reiberger Thomas, Bosch Jaume, García Pagán Juan Carlos, Mandorfer Mattias, A study by the Baveno Cooperation: an EASL consortium. Non-invasive tests for clinically significant portal hypertension after HCV cure.. Journal of hepatology. 2022. DOI: 10.1016/j.jhep.2022.08.025.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.